Novo Nordisk's once-daily oral weight-loss therapy Wegovy pill has crossed a historic milestone—1 million patients treated and $355 million in sales—yet the company's stock has tumbled as investors fret over intensifying competition from Eli Lilly and a crowded GLP-1 market. The Danish drugmaker is now executing a two-pronged strategy: expand the pill's global footprint while aggressively cutting costs, all under the leadership of CEO Mike Doustdar.

A Blockbuster in the Making

According to BioSpace, the Wegovy pill has shattered expectations, reaching 1 million patients and pulling in $355 million in sales. Morningstar reports that prescriptions have surpassed 3 million globally, with one filled roughly every five seconds. Critically, the drug is expanding the market rather than merely cannibalizing existing injections: MSN quotes CEO Doustdar saying that 80% of Wegovy pill customers have never taken a GLP-1 therapy before.

“The pillar of our strategy is to bring GLP-1 therapy to people with obesity who were previously untreated,” Doustdar told Bloomberg Television.

Proactive Investors described the pill as on track for blockbuster status, despite the increasingly crowded weight-loss market.

Investors Unimpressed Despite Profit Beat

Reuters noted that the weight-loss pill powered a profit beat, helping Novo Nordisk in its race to catch Eli Lilly. Yet Invezz reported that the stock fell despite an outlook hike, as Wegovy pill sales missed some bullish estimates. WSJ echoed the sentiment, saying shares plummeted as competition weighed on sales.

The disconnect underscores the market's laser focus on the competitive dynamics shaping the obesity drug space. While the oral pill is growing rapidly, Eli Lilly—the maker of rival injectables Mounjaro and Zepbound—has been gaining ground. Lilly recently lifted its profit forecast, citing surging demand for weight-loss drugs that offsets pricing pressure, according to Reuters.

Competitive Pressures Mount

Lilly's Momentum

Eli Lilly has emerged as the primary challenger to Novo’s dominance. The company’s profit forecast upgrade reflects bulging demand for its incretin-based therapies. Lilly is also advancing its own oral candidates, and CNBC reports that drugmakers are racing to find a place in the next wave of obesity drugs, with Pfizer and others entering the fray. The Guardian framed the situation bluntly: “Ozempic maker struggles as it loses ground to rivals in the weight-loss market.”

Amazon Pharmacy Enters

The competitive threat extends beyond clinical trials. Retail giant Amazon Pharmacy has begun stocking Eli Lilly's new weight-loss pill, a move that 247wallst.com says could reshape drug distribution and convenience. Amazon’s massive delivery network may make these drugs more accessible than ever, intensifying price and market-share pressure.

Novo Nordisk's Counterattack

Global Expansion and Cost Cuts

To counter the pressure, Novo Nordisk is pursuing several levers. Reuters reports that the company will soon seek approval to sell the Wegovy pill in China, a massive potential market. FiercePharma notes that Novo has already gained a head start over Lilly with European Commission approval of the pill.

The company is also trimming its workforce to stay lean. In a dramatic move, Novo Nordisk announced it will slash 9,000 jobs—roughly 10% of its workforce—to streamline operations in the fierce weight-loss drug battle, Reuters exclusively reported.

CEO's Perspective

CEO Mike Doustdar defended the company’s strategy and the pill’s economics:

“Profitability is decent and will keep improving,” he told Bloomberg. “If that was not the case, we would not be launching the product in more and more markets.”

The Wall Street Journal asks pointedly whether the new CEO can stop rivals from taking over the anti-obesity market—a question that hangs over every strategic move. Doustdar's emphasis on first-time GLP-1 users is key. If the pill is drawing in patients who previously shunned injections, Novo may be expanding the total addressable market—a narrative that could ultimately quiet skeptics.

Investor Sentiment Begins to Turn

Despite the share swoon, some analysts see a buying opportunity. Inkl's analysis asks whether investors should buy the post-earnings plunge or stay away, while Reuters notes that Novo is starting its “fight back” as investors return. Novo Holdings, the parent company, nearly doubled its earnings in the period, bolstered by Wegovy’s swelling coffers, according to Yahoo Finance.

Outlook and Implications

The battle for obesity market supremacy is far from over. With Lilly raising forecasts, Amazon entering distribution, and Novo Nordisk cutting costs while pushing into China, the next few quarters will be pivotal. For patients, the competition could mean better access and lower prices. For investors, the stakes are enormous.

  • Wegovy pill: 1M+ patients, $355M sales, 3M+ prescriptions.
  • Novo’s workforce reduction: 9,000 jobs cut.
  • Geographic expansion: China submission planned; EU already approved.
  • Key competitive threats: Lilly’s profit surge; Amazon Pharmacy distribution.

Sources: Bloomberg, Reuters, BioSpace, The Guardian, WSJ, Invezz, Morningstar, FiercePharma, MSN, Yahoo Finance, CNBC, 247wallst, Inkl, Proactive Investors.